Skip to main content

Table 1 HIV-1 interactions with approved drug target genes, by HIV-1 element.

From: JNets: Exploring networks by integrating annotation

HIV-1 element Total interactions Interactions with drug target genes Corrected p
Env-gp120 856 (22%) 239 (29%) 5.85 × 10-6
Integrase 102 (3%) 5 (1%) 7.15 × 10-4
Rev 109 (3%) 7 (1%) 1.36 × 10-3
Env-gp41 190 (5%) 58 (7%) 4.65 × 10-3
Tat 1394 (35%) 249 (30%) 2.50 × 10-2
Capsid 45 (1%) 16 (2%) 6.23 × 10-2
Vif 77 (2%) 8 (1%) 6.57 × 10-2
Nef 302 (8%) 78 (10%) 7.60 × 10-2
Pol 1 (< 1%) 0 (0%) 0.238
Vpr 275 (7%) 47 (6%) 0.173
Env-gp160 213 (5%) 49 (6%) 0.432
Env-gp41 190 (5%) 58 (7%) 1.07 × 10-2
Rev 109 (3%) 7 (1%) 4.50 × 10-3
Integrase 102 (3%) 5 (1%) 2.61 × 10-3
Matrix 95 (2%) 15 (2%) 0.399
Retropepsin 89 (2%) 15 (2%) 0.506
Vif 77 (2%) 8 (1%) 0.120
Gag 72 (2%) 15 (2%) 0.889
Reverse transcriptase 45 (1%) 8 (1%) 0.605
Vpu 27 (1%) 5 (1%) 0.667
Nucleocapsid 26 (1%) 4 (< 1%) 0.486
p6 18 (< 1%) 2 (< 1%) 0.386
p1 3 (< 1%) 0 (0%) 0.253
  1. The proportion of interactions that HIV-1 has with the products of genes that also encode drug targets, compared to total interactions, grouped by HIV-1 element are shown. The statistical significance of the difference in expected and actual figures, indicated by p-values, were calculated in JNets using two-tailed Chi-square tests, corrected for multiple testing using the Benjamini and Hochberg method [15]. Using a p cutoff of 0.05, we found significantly more Env-gp120 and Env-gp41 interactions and significantly fewer Tat, Integrase and Rev interactions among drug target genes, than would be expected at random.